New incubator to promote drug discovery and create new therapeutics companies in Singapore
Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch "65LAB"
Evotec SE announced that the Company has entered into a new BRIDGE partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund. “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.
The first collaboration of its kind in Singapore, 65LAB was initiated by Lightstone Ventures with Evotec to leverage the global capabilities of its partners – including financing, networks, company creation, and drug development expertise – to identify and accelerate the commercialisation of the most promising research from top academic and R&D institutions in Singapore, the Agency for Science, Technology and Research (“A*STAR”), the National University of Singapore (“NUS”) and Duke-NUS Medical School (a collaboration between Duke University and NUS). 65LAB aims to combine Evotec’s end-to-end integrated R&D platform and product development strength with Singapore’s first-class academic and translational science, it’s growing biotech infrastructure and capabilities to ultimately create breakthrough therapies with a global health impact.
65LAB was founded to establish a model of long-term partnership to foster future company growth and the development of Singapore’s biotech ecosystem. 65LAB selects promising academic projects and invests up to US$ 1.5 m in each project over the course of 18-24 months. The collaboration enables scientists in partner institutions to accelerate their therapeutic innovations through the support of Evotec’s Expert-in-Residence, as well as direct access to the life science company’s drug discovery, translational and development capabilities across disease areas and therapeutic modalities. Upon completion, projects will be evaluated by 65LAB’s board of global investors for further investment and the creation of new companies.
The core of the 65LAB collaboration is its Singapore-based academic and R&D partners, whose research discoveries will be translated with the goal to potentially achieve commercial success and create positive patient impact. Singapore’s public sector academic and translational researchers bring expertise across multiple modalities of treatment and disease areas of high unmet need.
65LAB’s Board of Directors is a team of world-leading biotech investors with broad expertise in company building and advancing a broad range of therapeutic modalities into and through the clinic. The Board provides oversight and governance to 65LAB’s strategy and operations and includes Dr Wen Qi Ho, Therapeutics Lead, ClavystBio, Dr Christina Isacson, Partner, Lightstone Ventures, Dr Pei Sze Ng, Director, Leaps by Bayer, and Dr Kim Png, Principal, Polaris Partners.
Dr Thomas Hanke, EVP Head of Academic Partnerships at Evotec, said: “Singapore has multiple world-renowned institutions for basic research in the life sciences. Through 65LAB, we are looking forward to translating their ground-breaking research into product candidates and new company formations that will benefit patients with unmet medical needs across all modalities and therapeutic areas.”
Dr Christina Isacson, Partner, Lightstone Ventures, said: “Lightstone has long been committed to supporting the growth of Singapore’s promising biotech sector, and we are thrilled at this opportunity to continue to foster and invest in the exciting drug development research coming out of the country’s universities. 65LAB is a unique entity, whose key differentiator is the syndicate of seasoned global life science investors who recognise the untapped potential of Singapore’s excellent base of scientific talent. We are pleased to partner with such a distinguished group of investors, who bring significant resources, experience and networks to transform these innovations into new medicines and bring them to market.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
